<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypnic headache</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypnic headache</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypnic headache</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">F Michael Cutrer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Elizabeth Robertson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypnic headache is an uncommon headache syndrome characterized by recurrent episodes of dull or throbbing head pain that develops only during sleep. It was previously termed "alarm clock headache" due to the characteristic early morning onset that awakens patients from sleep.</p><p>This topic will discuss hypnic headache. Other uncommon headache syndromes characterized by recurrent episodes of brief head pain are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3363.html" rel="external">"Exercise (exertional) headache"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3362.html" rel="external">"Primary headache associated with sexual activity"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3325.html" rel="external">"Primary cough headache"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3327.html" rel="external">"Primary stabbing headache"</a>.)</p><p></p><p class="headingAnchor" id="H1400716693"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Hypnic headache is one of the few headache disorders to occur almost exclusively in later life. The onset of hypnic headache typically occurs after age 50 years, although some cases in patients younger than age 40 years have been reported [<a href="#rid1">1-4</a>]. In addition, a few cases of hypnic headache in children have also been reported, including those as young as three years old [<a href="#rid5">5-7</a>].</p><p>Hypnic headache appears to be a rare condition, but the actual incidence and prevalence are unknown. In data from tertiary headache centers and clinics, the overall proportion of patients with hypnic headache ranged from 0.07 to 0.35 percent, while the proportion among older patients (age ≥65 years old) with headache ranged from 1.4 to 1.7 percent [<a href="#rid2">2</a>].</p><p>Hypnic headache is more common among female adults and female children, with an overall predominance of approximately 2:1 [<a href="#rid2">2-4,7</a>].</p><p class="headingAnchor" id="H140597361"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The cause of primary hypnic headache is not understood. The circadian pattern and association with sleep suggest a pathophysiologic connection with hypothalamic dysfunction [<a href="#rid3">3,8</a>]. In a voxel-based morphometric MRI study, gray matter volume in the posterior hypothalamus was lower in patients with hypnic headache than in matched controls [<a href="#rid9">9</a>]. An earlier report using similar methods found increased gray matter volume in a similar location among patients with cluster headache [<a href="#rid10">10</a>]. Nevertheless, both studies implicate the posterior hypothalamus in headache disorders with a tendency toward cyclical and nocturnal occurrence.</p><p>Hormonal changes have also been implicated in the etiology of hypnic headache. Hypnic headache has been reported to occur following weaning from <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> therapy [<a href="#rid11">11</a>] which can alter melatonin and serotonin levels and influence circadian rhythmicity [<a href="#rid12">12</a>].</p><p>Although early reports suggested that hypnic headache might be a rapid eye movement (REM) sleep disorder, later studies showed that the majority of hypnic headache attacks arise from non-REM sleep stages, mainly sleep stage N2 [<a href="#rid3">3,8</a>].</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H2106077993"><span class="h2">Temporal features</span><span class="headingEndMark"> — </span>Hypnic headache has also been called "alarm clock" headache because it develops during sleep and awakens patients from sleep [<a href="#rid13">13</a>]. The most common time of headache onset is between midnight and four o’clock in the morning [<a href="#rid2">2,4</a>].</p><p>For most patients with hypnic headache, symptoms typically persist for 15 minutes up to two hours after awakening, although longer durations may occur. In one large review of 343 patients with hypnic headache, the mean headache duration was 94 minutes [<a href="#rid4">4</a>].</p><p>Hypnic headache attacks occur frequently (≥10 days per month) and may occur daily for many patients [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H4214815041"><span class="h2">Headache features</span><span class="headingEndMark"> — </span>The pain in hypnic headache is typically dull or throbbing in character and moderate or severe in intensity [<a href="#rid2">2,4</a>]. However, some patients report pulsatile or stabbing/burning pain. Up to two-thirds of patients have bilateral head pain, often frontotemporal in location, but others have unilateral or even holocephalic pain [<a href="#rid4">4</a>].</p><p>Most patients report engaging in some type of motor activity (eg, getting out of bed and eating, drinking, showering, or reading) when awakened by headache, but they typically do not exhibit the restless pacing that is associated with cluster headache [<a href="#rid3">3</a>].</p><p>Migrainous features such as nausea and phonophobia/photophobia occur in a minority of patients. Cranial autonomic features such as rhinorrhea/nasal congestion, lacrimation, and ptosis are uncommon, occurring in less than 10 percent of cases [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H1042022942"><span class="h2">Comorbid conditions</span><span class="headingEndMark"> — </span>Many patients with hypnic headache have other primary headache disorders such as migraine or tension-type headaches [<a href="#rid14">14</a>]. Migraine history appears to be the most common headache syndrome, reported to occur in as many as 40 to 50 percent [<a href="#rid15">15,16</a>].</p><p>Other comorbid conditions frequently reported in patients with hypnic headache include hypertension, seizures, and obstructive sleep apnea (OSA) [<a href="#rid3">3</a>]. The relationship between these conditions and hypnic headache is uncertain. They may occur as independent conditions, as both hypertension and OSA are common conditions, especially in older patients. However, cases of hypnic headache attributed to nocturnal hypertension have also been reported [<a href="#rid17">17,18</a>]. Symptoms improved with treatment of hypertension in these cases.</p><p>Morning headaches may occur as a presenting feature of OSA and may mimic hypnic headaches. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H140597446"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Hypnic headache should be considered in patients with recurring headaches that cause awakening from sleep. The diagnosis of hypnic headache is made in patients with symptoms that fulfill diagnostic criteria after diagnostic evaluation to exclude other causes to the symptoms [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H1592044113"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Diagnostic criteria for hypnic headache, according to the International Classification of Headache Disorders third edition (ICHD-3), are as follows [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A) Recurrent headache attacks fulfilling criteria B through E</p><p class="bulletIndent1"><span class="glyph">●</span>B) Developing only during sleep and causing wakening</p><p class="bulletIndent1"><span class="glyph">●</span>C) Occurring on ≥10 days per month for more than three months</p><p class="bulletIndent1"><span class="glyph">●</span>D) Lasting ≥15 minutes and for up to four hours after waking</p><p class="bulletIndent1"><span class="glyph">●</span>E) No cranial autonomic symptoms or restlessness</p><p class="bulletIndent1"><span class="glyph">●</span>F) Not better accounted for by another ICHD-3 diagnosis</p><p></p><p>One area of debate is that the ICHD-3 criteria exclude the diagnosis of hypnic headache if there are associated cranial autonomic symptoms (tearing, runny nose, ptosis, or miosis) or restlessness, features that can be prominent in cluster headache and other trigeminal autonomic cephalalgias [<a href="#rid1">1</a>]. However, cranial autonomic features can accompany hypnic headache in a small proportion of cases [<a href="#rid2">2</a>]. (See <a class="local">'Headache features'</a> above.)</p><p class="headingAnchor" id="H1302201598"><span class="h2">Evaluation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuroimaging</strong> – For all patients with new nocturnal headache, we suggest neuroimaging of the brain to evaluate for structural causes. We prefer brain magnetic resonance imaging (MRI) with gadolinium contrast. Head computed tomography (CT) with contrast may be performed as an alternative imaging test for patients with a contraindication to MRI but has a lower sensitivity and exposes patients to radiation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other testing for selected patients</strong> – Additional testing is generally performed for patients with features atypical for hypnic headache and those with additional symptoms suggestive of an alternative diagnosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We obtain erythrocyte sedimentation rate and C-reactive protein for patients with features suggestive of giant cell arteritis, such as those with atypical headaches (eg, scalp tenderness, associated visual changes) and those with additional constitutional symptoms (eg, fever, weight loss, jaw claudication). (See  <a class="medical medical_review" href="/z/d/html/8242.html" rel="external">"Diagnosis of giant cell arteritis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We assess for obstructive sleep apnea (OSA) for at-risk patients with excessive daytime sleepiness and those with both clinical features consistent with OSA (eg, obesity, snoring) and conditions associated with OSA (eg, atrial fibrillation, congestive heart failure)  (<a class="graphic graphic_table graphicRef55633" href="/z/d/graphic/55633.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ambulatory blood pressure monitoring may be helpful to detect nocturnal hypertension for selected patients with symptoms of hypnic headache associated with a new diagnosis or suboptimal control of hypertension [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/3820.html" rel="external">"Out-of-office blood pressure measurement: Ambulatory and self-measured blood pressure monitoring"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Electroencephalography (EEG) should be performed when seizures are suspected, such as for patients with morning headaches and confusion or transient neurologic deficits. Ambulatory EEG may increase diagnostic yield when routine EEG is nondiagnostic. (See  <a class="medical medical_review" href="/z/d/html/2233.html" rel="external">"Electroencephalography (EEG) in the diagnosis of seizures and epilepsy"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of hypnic headache includes other conditions that present with recurrent headaches that occur during sleep or at awakening. These conditions include both primary and secondary headaches, as well as structural intracranial and some systemic conditions. These alternative causes may be discriminated from hypnic headache by specific clinical features or results of diagnostic testing.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Headache disorders</strong> – Other headache conditions that may mimic hypnic headache include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Migraine (see  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Cluster headache (see  <a class="medical medical_review" href="/z/d/html/3326.html" rel="external">"Cluster headache: Epidemiology, clinical features, and diagnosis"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Chronic and episodic paroxysmal hemicrania (see  <a class="medical medical_review" href="/z/d/html/3334.html" rel="external">"Paroxysmal hemicrania: Clinical features and diagnosis"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Medication overuse headache (see  <a class="medical medical_review" href="/z/d/html/3340.html" rel="external">"Medication overuse headache: Etiology, clinical features, and diagnosis"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Cervicogenic headache (see  <a class="medical medical_review" href="/z/d/html/3354.html" rel="external">"Cervicogenic headache"</a>)</p><p></p><p class="bulletIndent1">The absence of daytime attacks is the main feature that distinguishes hypnic headache from most other headache types. Other discriminating features vary by form of headache. Migraine may be the most common alternative headache disorder as it can both mimic and be comorbid with hypnic headache. Features suggestive of the diagnosis of migraine include presence of aura and prominent migrainous symptoms (eg, nausea, photophobia, or phonophobia) [<a href="#rid3">3</a>]. Features suggestive of cluster headache or paroxysmal hemicrania include severe pain, prominent cranial autonomic symptoms, and multiple daily attacks. Medication overuse headache may be identified by eliciting a history of medication use, such as opioids, barbiturates, simple and combination analgesics, triptans, and polypharmacy. Patients with cervicogenic headache typically report unilateral head pain that is aggravated by head or neck movement/positioning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intracranial structural causes</strong> – The differential diagnosis of hypnic headache also includes headaches caused by structural intracranial conditions that result in elevated intracranial pressure or traction on nociceptor-containing dural membranes. These conditions may be identified with brain imaging and include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary or metastatic tumor [<a href="#rid19">19,20</a>] (see  <a class="medical medical_review" href="/z/d/html/14113.html" rel="external">"Brain tumor headache"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Vestibular schwannoma [<a href="#rid21">21</a>] (see  <a class="medical medical_review" href="/z/d/html/5222.html" rel="external">"Vestibular schwannoma (acoustic neuroma)"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Subdural hematoma [<a href="#rid22">22</a>] (see  <a class="medical medical_review" href="/z/d/html/1105.html" rel="external">"Subdural hematoma in adults: Etiology, clinical features, and diagnosis"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Obstructive hydrocephalus [<a href="#rid23">23</a>] (see  <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">"Evaluation and management of elevated intracranial pressure in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic conditions</strong> – Some systemic conditions may present with headache symptoms that may mimic hypnic headache. However, the headache in many of these conditions does not typically occur exclusively at awakening from sleep, in contradistinction to hypnic headache. In addition, these conditions may also feature additional symptoms not found in patients with hypnic headache. These conditions include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Obstructive sleep apnea</strong> – Headache may be a presenting feature of obstructive sleep apnea (OSA). Headache may occur daily. However, daytime sleepiness and other features associated with this condition are not found in patients with hypnic headache. Headaches attributed to OSA typically resolve with positive airway pressure or another treatment for the condition. (See  <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nocturnal hypertension</strong> – Patients with new or suboptimal control of hypertension with nocturnal blood pressure spikes may develop symptoms suggestive of hypnic headache [<a href="#rid17">17,18,24</a>]. In these cases, headache symptoms resolve with effective treatment of hypertension.</p><p></p><p class="bulletIndent2">Pheochromocytoma can also cause fluctuating blood pressure, including nocturnal hypertension. In addition to headache, patients with pheochromocytoma typically present with episodic sweating and tachycardia. Patients may also have episodic or sustained hypertension. Testing to identify catecholamine hypersecretion is used to diagnose pheochromocytoma. (See  <a class="medical medical_review" href="/z/d/html/130.html" rel="external">"Clinical presentation and diagnosis of pheochromocytoma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Giant cell arteritis</strong> – The headache of giant cell arteritis is often nonspecific and can mimic other headache disorders including hypnic headache. However, some patients report scalp tenderness, and the condition may also be identified by the presence of constitutional symptoms (eg, fatigue, fever, weight loss) as well as vision loss. (See  <a class="medical medical_review" href="/z/d/html/8225.html" rel="external">"Clinical manifestations of giant cell arteritis"</a>.)</p><p></p><p class="bulletIndent2">Diagnostic testing including erythrocyte sedimentation rate and C-reactive protein levels should be performed for patients with suspected giant cell arteritis. (See  <a class="medical medical_review" href="/z/d/html/8242.html" rel="external">"Diagnosis of giant cell arteritis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seizures</strong> – Patients with nocturnal seizures may awaken with postictal headache. Other features suggestive of seizure over primary hypnic headache include headache associated with confusion or incontinence or a history of seizures. Electroencephalography (EEG) is warranted for patients with suspected postictal headache. (See  <a class="medical medical_review" href="/z/d/html/2223.html" rel="external">"Seizures and epilepsy in older adults: Etiology, clinical presentation, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2">OSA and seizures can also be comorbid with hypnic headache. (See <a class="local">'Comorbid conditions'</a> above.)</p><p></p><p class="headingAnchor" id="H5"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Pharmacologic treatment is the mainstay of the management of hypnic headache. We typically use with preventive therapy because most patients with hypnic headache have frequent or daily recurring headaches. Acute treatment is used for symptomatic patients with breakthrough pain.</p><p class="headingAnchor" id="H802125995"><span class="h2">Acute treatment</span><span class="headingEndMark"> — </span>We suggest <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">caffeine</a> for symptomatic treatment of hypnic headache. We typically start with caffeinated beverages such as coffee or a single dose of a caffeine oral tablet (eg, 65 to 200 mg). Alternative options include caffeine-containing combination oral analgesics such as a tablet of combined <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> 250 mg, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 250 mg, and caffeine 65 mg. The effectiveness of caffeine for acute treatment of hypnic headache ranges from 60 to nearly 85 percent in case series [<a href="#rid2">2,15,25</a>].</p><p>Other options that have been used for acute treatment of hypnic headache include simple analgesics (eg, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, nonsteroidal antiinflammatory drugs), ergotamines, and triptans [<a href="#rid15">15,25,26</a>].</p><p class="headingAnchor" id="H3888350244"><span class="h2">Preventive treatment</span></p><p class="headingAnchor" id="H2105147950"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>For most patients with hypnic headache, we suggest initial preventive therapy with either <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">caffeine</a> at bedtime or <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a>. The selection of agent varies by patient preference and adverse effect profile. Caffeine is available without prescription, including as coffee or another beverage, but may impair sleep when taken at bedtime. Indomethacin may be preferred for patients with other indications for nonsteroidal antiinflammatory medications such as rheumatoid or osteoarthritis.</p><p>Options and typical dosing for initial preventive treatment of hypnic headache include either of the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Caffeine</strong> – Given as a tablet (65 to 200 mg) or beverage at bedtime [<a href="#rid25">25,27</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indomethacin</strong> – Administered at 50 mg three times daily [<a href="#rid28">28</a>]</p><p></p><p>We typically continue preventive therapy for three to six months before attempting to wean [<a href="#rid2">2</a>]. For patients with recurrent symptoms, we resume treatment. The evidence of efficacy of these medications is limited to small case series. The response rate to <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">caffeine</a> or <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a> in various studies ranges from approximately 50 to 60 percent [<a href="#rid2">2,15,25,27,29</a>].</p><p class="headingAnchor" id="H3517553453"><span class="h3">Alternative options</span><span class="headingEndMark"> — </span>For patients with a contraindication or inadequate response to initial therapy, we switch to or add an alternative medication such as <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, melatonin, or <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lithium</strong> – The starting dose of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> carbonate is 300 mg once daily and may be increased after one week to 600 mg once daily as needed and tolerated [<a href="#rid13">13,27,30</a>]. Laboratory monitoring prior to starting lithium and for ongoing surveillance includes urinalysis, kidney function studies, thyroid function, and electrolytes. In addition, an electrocardiogram should be performed to assess for conduction abnormalities.</p><p></p><p class="bulletIndent1">Nonsteroidal antiinflammatory drugs should be avoided when taking <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, if possible, as these agents can increase lithium levels in the blood and increase the risk for serious adverse effects.</p><p></p><p class="bulletIndent1">The most common acute side effects associated with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> are nausea, tremor, polyuria and thirst, weight gain, loose stools, and cognitive impairment. Severe or a sudden worsening of side effects may be a sign of lithium toxicity. Important long-term adverse effects of lithium involve kidney and thyroid dysfunction as well as cardiac rhythm disturbances. (See  <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Laboratory tests and monitoring'</a> and  <a class="medical medical_review" href="/z/d/html/7843.html" rel="external">"Lithium and the thyroid"</a> and  <a class="medical medical_review" href="/z/d/html/2358.html" rel="external">"Renal toxicity of lithium"</a>.)</p><p></p><p class="bulletIndent1">Case series have reported response rates of 70 to 80 percent with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> [<a href="#rid31">31-33</a>]. However, lithium is a second-line agent for hypnic headache due to its narrow therapeutic index, particularly in older adult patients, and is contraindicated in those with significant cardiovascular disease or kidney impairment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Melatonin</strong> – Small case series have reported up to 50 percent response rates with melatonin [<a href="#rid4">4,27,34</a>]. Melatonin is typically given at doses of 3 to 5 mg at bedtime.</p><p></p><p class="bulletIndent1">Adverse effects of melatonin include vivid dreams, dizziness, and sedation. Melatonin is a dietary supplement available in the United States by several formulations including tablets, patches, and liquids. However, melatonin is available only by prescription in several other countries. (See  <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">"Pharmacotherapy for insomnia in adults", section on 'Melatonin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amitriptyline</strong> – Low doses of <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>, typically 10 to 50 mg once each night, may be effective for some patients with hypnic headache [<a href="#rid15">15</a>]. In several case studies and reports, the response rate with amitriptyline or other tricyclic antidepressants is approximately 20 percent [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1">Baseline testing prior to starting <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> includes electrolytes to assess for hypokalemia and an electrocardiogram to assess for conduction abnormalities. Common adverse effects with amitriptyline include sedation, confusion, and cardiac conduction disturbances. It should be used with caution in patients with a history of cardiovascular disease. (See  <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">"Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"</a>.)</p><p></p><p>Several other medications have also been reported to be effective in case reports of hypnic headache including:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a> 25 to 100 mg daily [<a href="#rid35">35,36</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8869" href="/z/d/drug information/8869.html" rel="external">Flunarizine</a> 5 mg at bedtime [<a href="#rid37">37</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> 325 mg plus <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">caffeine</a> 40 mg at bedtime [<a href="#rid25">25</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">Atenolol</a> 25 mg at bedtime [<a href="#rid25">25</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">Lamotrigine</a> 25 to 75 mg daily [<a href="#rid38">38</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Botulinum toxin [<a href="#rid39">39,40</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> 25 mg daily for 15 days, then 12.5 mg daily for 15 days [<a href="#rid41">41</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Sodium ferulate 75 to 300 mg daily in three divided doses [<a href="#rid42">42</a>]</p><p></p><p class="headingAnchor" id="H140597637"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Hypnic headache is a chronic disorder that can last for years, though a substantial proportion of patients may respond to treatment. However, the natural history of hypnic headache is not well studied. In one review, the average time from onset to the correct diagnosis of hypnic headache was five years [<a href="#rid3">3</a>]. A systematic review of hypnic headache reported outcomes in 72 patients with follow-up ranging from six months to five years [<a href="#rid2">2</a>]. Symptoms persisted in 47 percent, resolved after treatment in 43 percent, recurred following an attempt to wean in 7 percent, and spontaneously resolved in 3 percent.</p><p class="headingAnchor" id="H3718760129"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110285.html" rel="external">"Society guideline links: Migraine and other primary headache disorders"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and epidemiology</strong> – Hypnic headache, also known as "alarm clock headache," occurs most commonly after the age of 50 years and is characterized by episodes of dull or throbbing head pain, often bilateral, that awaken the patient from sleep. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Hypnic headache typically occurs between midnight and four o’clock in the morning. The headache is often bilateral, dull or throbbing in character, and moderate or severe in intensity. It typically persists for 15 minutes up to two hours after awakening. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and evaluation</strong> – The diagnosis of hypnic headache is made in patients with symptoms that fulfill diagnostic criteria after diagnostic evaluation to exclude other causes to the symptoms. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">For all patients with new nocturnal headache, we suggest brain MRI with gadolinium to evaluate for structural causes. Additional testing is generally performed for patients with features atypical for hypnic headache and those with additional symptoms suggestive of an alternative diagnosis. Testing may include laboratory testing (eg, erythrocyte sedimentation rate and C-reactive protein), ambulatory blood pressure monitoring, polysomnography, and electroencephalography (EEG). (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute treatment</strong> – We suggest <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">caffeine</a> for symptomatic treatment of hypnic headache (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically start with caffeinated beverages such as coffee or a single dose of a caffeine oral tablet (eg, 65 to 200 mg). Alternative options include caffeine-containing combination oral analgesics such as a tablet of combined <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> 250 mg, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 250 mg, and caffeine 65 mg.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preventive treatment</strong> – For most patients with hypnic headache, we suggest initial preventive therapy with either <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">caffeine</a> at bedtime or <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The selection of agent varies by patient preference and adverse effect profile. Caffeine may be given as a tablet (65 to 200 mg) or as a beverage at bedtime. Indomethacin is typically given at 50 mg three times daily. In case series, approximately half of patients respond to either of these medications. (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent2">We use an alternative agent for patients who do not respond to initial preventive therapy. Options include <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> carbonate (300 to 600 mg daily), melatonin (3 to 5 mg at bedtime), or <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> (10 to 50 mg at bedtime). Response rates may be highest with lithium, but the agent may be poorly tolerated or contraindicated for many older adult patients. Melatonin and amitriptyline may cause sedation, and amitriptyline should be used with caution in patients with cardiovascular disease. (See <a class="local">'Alternative options'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Hypnic headache is a chronic disorder that can last for years, though a substantial proportion of patients may respond to treatment. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.</a></li><li><a class="nounderline abstract_t">Liang JF, Wang SJ. Hypnic headache: a review of clinical features, therapeutic options and outcomes. Cephalalgia 2014; 34:795.</a></li><li><a class="nounderline abstract_t">Holle D, Naegel S, Obermann M. Hypnic headache. Cephalalgia 2013; 33:1349.</a></li><li><a class="nounderline abstract_t">Silva-Néto RP, Santos PEMS, Peres MFP. Hypnic headache: A review of 348 cases published from 1988 to 2018. J Neurol Sci 2019; 401:103.</a></li><li><a class="nounderline abstract_t">Cerminara C, Compagnone E, Coniglio A, et al. Hypnic headache in children. Cephalalgia 2011; 31:1673.</a></li><li><a class="nounderline abstract_t">Scagni P, Pagliero R. Hypnic headache in childhood: a new case report. J Paediatr Child Health 2008; 44:83.</a></li><li><a class="nounderline abstract_t">Ferretti A, Velardi M, Fanfoni C, et al. Pediatric hypnic headache: a systematic review. Front Neurol 2023; 14:1254567.</a></li><li><a class="nounderline abstract_t">Holle D, Naegel S, Obermann M. Pathophysiology of hypnic headache. Cephalalgia 2014; 34:806.</a></li><li><a class="nounderline abstract_t">Holle D, Naegel S, Krebs S, et al. Hypothalamic gray matter volume loss in hypnic headache. Ann Neurol 2011; 69:533.</a></li><li><a class="nounderline abstract_t">May A, Ashburner J, Büchel C, et al. Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nat Med 1999; 5:836.</a></li><li><a class="nounderline abstract_t">Karlovasitou A, Avdelidi E, Andriopoulou G, Baloyannis S. Transient hypnic headache syndrome in a patient with bipolar disorder after the withdrawal of long-term lithium treatment: a case report. Cephalalgia 2009; 29:484.</a></li><li><a class="nounderline abstract_t">Seggie J, Werstiuk ES, Grota L. Lithium and circadian patterns of melatonin in the retina, hypothalamus, pineal and serum. Prog Neuropsychopharmacol Biol Psychiatry 1987; 11:325.</a></li><li><a class="nounderline abstract_t">Raskin NH. The hypnic headache syndrome. Headache 1988; 28:534.</a></li><li><a class="nounderline abstract_t">Mulero P, Guerrero-Peral AL, Cortijo E, et al. [Hypnic headache: characteristics of a series of 13 new cases and proposal for modification of the diagnostic criteria]. Rev Neurol 2012; 54:129.</a></li><li><a class="nounderline abstract_t">Holle D, Naegel S, Krebs S, et al. Clinical characteristics and therapeutic options in hypnic headache. Cephalalgia 2010; 30:1435.</a></li><li><a class="nounderline abstract_t">Donnet A, Lantéri-Minet M. A consecutive series of 22 cases of hypnic headache in France. Cephalalgia 2009; 29:928.</a></li><li><a class="nounderline abstract_t">Caminero AB, Martín J, Sánchez del Río M. Secondary hypnic headache or symptomatic nocturnal hypertension? Two case reports. Cephalalgia 2010; 30:1137.</a></li><li><a class="nounderline abstract_t">Gil-Gouveia R, Goadsby PJ. Secondary "hypnic headache". J Neurol 2007; 254:646.</a></li><li><a class="nounderline abstract_t">Peatfield RC, Mendoza ND. Posterior fossa meningioma presenting as hypnic headache. Headache 2003; 43:1007.</a></li><li><a class="nounderline abstract_t">Mullally WJ, Hall KE. Hypnic headache secondary to haemangioblastoma of the cerebellum. Cephalalgia 2010; 30:887.</a></li><li><a class="nounderline abstract_t">Ceronie B, Green F, Cockerell OC. Acoustic neuroma presenting as a hypnic headache. BMJ Case Rep 2021; 14.</a></li><li><a class="nounderline abstract_t">Yamada SM, Tomita Y, Murakami H, et al. Headache in patients with chronic subdural hematoma: analysis in 1080 patients. Neurosurg Rev 2018; 41:549.</a></li><li><a class="nounderline abstract_t">Shaktawat SS, Salman WD, Twaij Z, Al-Dawoud A. Unexpected death after headache due to a colloid cyst of the third ventricle. World J Surg Oncol 2006; 4:47.</a></li><li><a class="nounderline abstract_t">Silva-Néto RP, Bernardino SN. Ambulatory blood pressure monitoring in patient with hypnic headache: a case study. Headache 2013; 53:1157.</a></li><li><a class="nounderline abstract_t">Dodick DW, Mosek AC, Campbell JK. The hypnic ("alarm clock") headache syndrome. Cephalalgia 1998; 18:152.</a></li><li><a class="nounderline abstract_t">Evers S, Goadsby PJ. Hypnic headache: clinical features, pathophysiology, and treatment. Neurology 2003; 60:905.</a></li><li><a class="nounderline abstract_t">Tariq N, Estemalik E, Vij B, et al. Long-Term Outcomes and Clinical Characteristics of Hypnic Headache Syndrome: 40 Patients Series From a Tertiary Referral Center. Headache 2016; 56:717.</a></li><li><a class="nounderline abstract_t">Buzzi MG, Cologno D, Formisano R, Caltagirone C. Hypnic headache responsive to indomethacin: second Italian case. Funct Neurol 2005; 20:85.</a></li><li><a class="nounderline abstract_t">Ghiotto N, Sances G, Di Lorenzo G, et al. Report of eight new cases of hypnic headache and mini-review of the literature. Funct Neurol 2002; 17:211.</a></li><li><a class="nounderline abstract_t">Newman LC, Lipton RB, Solomon S. The hypnic headache syndrome: a benign headache disorder of the elderly. Neurology 1990; 40:1904.</a></li><li><a class="nounderline abstract_t">Silva-Néto RP, Almeida KJ. Hypnic headache: a descriptive study of 25 new cases in Brazil. J Neurol Sci 2014; 338:166.</a></li><li><a class="nounderline abstract_t">Liang JF, Fuh JL, Yu HY, et al. Clinical features, polysomnography and outcome in patients with hypnic headache. Cephalalgia 2008; 28:209.</a></li><li><a class="nounderline abstract_t">Holle D, Wessendorf TE, Zaremba S, et al. Serial polysomnography in hypnic headache. Cephalalgia 2011; 31:286.</a></li><li><a class="nounderline abstract_t">Dodick DW. Polysomnography in hypnic headache syndrome. Headache 2000; 40:748.</a></li><li><a class="nounderline abstract_t">Guido M, Specchio LM. Successful treatment of hypnic headache with topiramate: a case report. Headache 2006; 46:1205.</a></li><li><a class="nounderline abstract_t">Autunno M, Messina C, Blandino A, Rodolico C. Hypnic headache responsive to low-dose topiramate: a case report. Headache 2008; 48:292.</a></li><li><a class="nounderline abstract_t">Morales-Asín F, Mauri JA, Iñiguez C, et al. The hypnic headache syndrome: report of three new cases. Cephalalgia 1998; 18:157.</a></li><li><a class="nounderline abstract_t">Ouahmane Y, Mounach J, Satte A, et al. Hypnic headache: response to lamotrigine in two cases. Cephalalgia 2012; 32:645.</a></li><li><a class="nounderline abstract_t">Marziniak M, Voss J, Evers S. Hypnic headache successfully treated with botulinum toxin type A. Cephalalgia 2007; 27:1082.</a></li><li><a class="nounderline abstract_t">Argyriou AA, Mitsikostas DD, Mantovani E, et al. Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders. Expert Rev Neurother 2021; 21:923.</a></li><li><a class="nounderline abstract_t">Relja G, Zorzon M, Locatelli L, et al. Hypnic headache: rapid and long-lasting response to prednisone in two new cases. Cephalalgia 2002; 22:157.</a></li><li><a class="nounderline abstract_t">Peng H, Wang L, He B, et al. Hypnic headache responsive to sodium ferulate in 2 new cases. Clin J Pain 2013; 29:89.</a></li></ol></div><div id="topicVersionRevision">Topic 3328 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24942086" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hypnic headache: a review of clinical features, therapeutic options and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23832130" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hypnic headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31075680" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hypnic headache: A review of 348 cases published from 1988 to 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22025767" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hypnic headache in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18086044" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hypnic headache in childhood: a new case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37638182" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pediatric hypnic headache: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24875926" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pathophysiology of hypnic headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21446025" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hypothalamic gray matter volume loss in hypnic headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10395332" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Correlation between structural and functional changes in brain in an idiopathic headache syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19170690" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Transient hypnic headache syndrome in a patient with bipolar disorder after the withdrawal of long-term lithium treatment: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2819953" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lithium and circadian patterns of melatonin in the retina, hypothalamus, pineal and serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3198388" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The hypnic headache syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22278889" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : [Hypnic headache: characteristics of a series of 13 new cases and proposal for modification of the diagnostic criteria].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20974580" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical characteristics and therapeutic options in hypnic headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19250282" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A consecutive series of 22 cases of hypnic headache in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20713565" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Secondary hypnic headache or symptomatic nocturnal hypertension? Two case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17404778" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Secondary "hypnic headache".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14511280" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Posterior fossa meningioma presenting as hypnic headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647180" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hypnic headache secondary to haemangioblastoma of the cerebellum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33687931" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Acoustic neuroma presenting as a hypnic headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28815322" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Headache in patients with chronic subdural hematoma: analysis in 1080 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16867192" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Unexpected death after headache due to a colloid cyst of the third ventricle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23425041" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ambulatory blood pressure monitoring in patient with hypnic headache: a case study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9595209" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The hypnic ("alarm clock") headache syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654950" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hypnic headache: clinical features, pathophysiology, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27015738" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-Term Outcomes and Clinical Characteristics of Hypnic Headache Syndrome: 40 Patients Series From a Tertiary Referral Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15966272" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hypnic headache responsive to indomethacin: second Italian case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12675265" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Report of eight new cases of hypnic headache and mini-review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2123309" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The hypnic headache syndrome: a benign headache disorder of the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24461515" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hypnic headache: a descriptive study of 25 new cases in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18254891" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical features, polysomnography and outcome in patients with hypnic headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20699335" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Serial polysomnography in hypnic headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11091295" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Polysomnography in hypnic headache syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16866729" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Successful treatment of hypnic headache with topiramate: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18081825" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hypnic headache responsive to low-dose topiramate: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9595210" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The hypnic headache syndrome: report of three new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22623758" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hypnic headache: response to lamotrigine in two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17645763" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hypnic headache successfully treated with botulinum toxin type A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34289791" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11972588" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hypnic headache: rapid and long-lasting response to prednisone in two new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22688604" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hypnic headache responsive to sodium ferulate in 2 new cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
